Besim Ogretmen to Treatment Outcome
This is a "connection" page, showing publications Besim Ogretmen has written about Treatment Outcome.
Connection Strength
0.129
-
HPV/E7 induces chemotherapy-mediated tumor suppression by ceramide-dependent mitophagy. EMBO Mol Med. 2017 08; 9(8):1030-1051.
Score: 0.062
-
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C18-ceramide as a novel biomarker for monitoring response. Clin Cancer Res. 2011 Sep 15; 17(18):6097-105.
Score: 0.041
-
A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Aug 15; 23(16):4642-4650.
Score: 0.015
-
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Blood. 2013 Sep 12; 122(11):1923-34.
Score: 0.012